Efficacy News and Research

RSS
Lexicon reports top-line results from LX2931 Phase 2a study in rheumatoid arthritis

Lexicon reports top-line results from LX2931 Phase 2a study in rheumatoid arthritis

Pharmasset initiates dosing in PSI-7977 exploratory study in HCV

Pharmasset initiates dosing in PSI-7977 exploratory study in HCV

Preliminary results from Phase 1b/2a trial of MediciNova's ibudilast in opioid addicts announced

Preliminary results from Phase 1b/2a trial of MediciNova's ibudilast in opioid addicts announced

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Nektar reports positive results from NKTR-102 Phase 2 study in metastatic breast cancer at CTRC-AACR SABCS

Nektar reports positive results from NKTR-102 Phase 2 study in metastatic breast cancer at CTRC-AACR SABCS

New collaboration to develop vaccine to prevent malaria parasite from entering human liver

New collaboration to develop vaccine to prevent malaria parasite from entering human liver

Study finds carotid artery stenting has higher risk of stroke and death than carotid endarterectomy

Study finds carotid artery stenting has higher risk of stroke and death than carotid endarterectomy

Immunomedics, UCB initiate enrollment in EMBODY 1 epratuzumab Phase III study in SLE

Immunomedics, UCB initiate enrollment in EMBODY 1 epratuzumab Phase III study in SLE

Top-line results from Inhibitex's FV-100 Phase II clinical trial for treatment of shingles

Top-line results from Inhibitex's FV-100 Phase II clinical trial for treatment of shingles

Capstone presents AZX100 Phase 2a trial results for keloid and trocar site scarring

Capstone presents AZX100 Phase 2a trial results for keloid and trocar site scarring

FDA to review Lantheus' DEFINITY sNDA for use in stress echocardiography

FDA to review Lantheus' DEFINITY sNDA for use in stress echocardiography

Lilly suspends tasisulam global Phase III study in metastatic melanoma

Lilly suspends tasisulam global Phase III study in metastatic melanoma

PREZISTA/ritonavir once-daily dosing for HIV-1 receives FDA approval for treatment in no DRV RAM adults

PREZISTA/ritonavir once-daily dosing for HIV-1 receives FDA approval for treatment in no DRV RAM adults

Intercell to stop further development of Travelers' Diarrhea Vaccine Patch

Intercell to stop further development of Travelers' Diarrhea Vaccine Patch

Bionovo reports positive Menerba clinical program meeting with FDA

Bionovo reports positive Menerba clinical program meeting with FDA

Women & Infants Hospital participates in new fertility drug study

Women & Infants Hospital participates in new fertility drug study

Vical's Vaxfectin adjuvant boosts immune response of DNA-based vaccines against cancer

Vical's Vaxfectin adjuvant boosts immune response of DNA-based vaccines against cancer

GeparQuinto study data on bevacizumab plus chemotherapy in early breast cancer to be presented at 33rd CTRC-AACR

GeparQuinto study data on bevacizumab plus chemotherapy in early breast cancer to be presented at 33rd CTRC-AACR

Presence of circulating tumor cells in early-stage breast cancer doubles risk of relapse and death

Presence of circulating tumor cells in early-stage breast cancer doubles risk of relapse and death

Xeloda may reduce recurrence of faster growing breast cancers: Study

Xeloda may reduce recurrence of faster growing breast cancers: Study

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.